PORTLAND, OR, UNITED STATES, January 6, 2025 /EINPresswire / -- The global immunoglobulin market is experiencing significant growth, driven by the increasing prevalence of immune-related diseases and ...
Belimumab is under clinical development by GSK and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 63% phase transition ...